Zacks Sell List Highlights: Integrated Circuit Systems, Xilinx Semiconductor, Fifth Third Bancorp, and Eyetech Pharmaceutical.CHICAGO -- Zacks.com releases details on a group of stocks that are part of their exclusive list of Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell). Since inception in 1988 the S&P 500 has outperformed the Zacks #5 Ranked Strong Sells by 141.8% annually (11.97% vs. 4.5% respectively). While the rest of Wall Street continued to tout stocks during the market declines of the last few years, we were telling our customers which stocks to sell or avoid. Among the #5 ranked stocks today we highlight the following companies: Integrated Circuit integrated circuit (IC), electronic circuit built on a semiconductor substrate, usually one of single-crystal silicon. The circuit, often called a chip, is packaged in a hermetically sealed case or a nonhermetic plastic capsule, with leads extending from it for Systems, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ICST ICST Imperial College of Science and Technology (UK) ICST Institute for Computer Science and Technology ICST Institute for Computer Sciences & Technology ICST Intra-Company Stock Transfer (retail) ) and Xilinx Semiconductor (NASDAQ:XLNX). Further they announced #4 Rankings (Sell) on two other widely held stocks: Fifth Third Bancorp (NASDAQ:FITB FITB Fill In The Blank FITB Future Income Tax Benefit FITB Fédération Internationale de Tchoukball (International Tchoukball Federation) ) and Eyetech Pharmaceutical, Inc. (NASDAQ:EYET). To see the full Zacks #5 Ranked list of Stocks to Sell Now then visit: http://at.zacks.com/?id=92 Here is a synopsis of why these stocks have a Zacks Rank of 5 (Strong Sell) and should most likely be sold or avoided for the next 1 to 3 months. Note that a #5/Strong Sell rating is applied to 5% of all the stocks we rank: Integrated Circuit Systems, Inc. (NASDAQ:ICST) is a worldwide leader in the design, development and marketing of silicon timing devices for a number of high-growth application segments. On September 16, after market close, Integrated Circuit Systems (ICS (1) (Internet Connection Sharing) A Windows feature that enables two or more computers to share one Internet connection. First introduced in Windows 98 Second Edition, sharing is accomplished with network address translation (NAT), which is the common method. ) lowered its September revenue guidance to flat to down 5% (versus prior guidance of 3%-7% growth) and an EPS (Encapsulated PostScript) A PostScript file format used to transfer a graphic image between applications and platforms. EPS files contain PostScript code as well as an optional preview image in TIFF, WMF, PICT or EPSI, the latter being an ASCII-only format. range of 22 cents to 24 cents vs. previous estimates of 26 cents. The company cited reduced demand in military and enterprise networking The networking infrastructure in a large enterprise with multiple computer systems and networks of different types is extraordinarily complex. Due to the myriad of interfaces that are required, much of what goes on has little to do with the real data processing of the payroll and orders. as the reasons for its revenue weakness. Analysts are following the company's guidance and estimates for both 2004 and 2005 are down over the last 60 days, -16 cents or -13.6% for 2004 and -23 cents or -17.6% for 2005. The company continues to expand its product mix and its current offering is being used in new applications that should aid in turning the revenue picture around, but for now, you may want to avoid a connection between ICST and your portfolio. Xilinx Semiconductor (NASDAQ:XLNX) develops and markets complete programmable logic See PLD. solutions, including advanced integrated circuits Integrated circuits Miniature electronic circuits produced within and upon a single semiconductor crystal, usually silicon. Integrated circuits range in complexity from simple logic circuits and amplifiers, about 1/20 in. (1. , software design tools, predefined system functions delivered as cores of logic and field engineering support. Xilinx recently announced its sales would fall 5-7% vs. previous guidance of 2-4%. Further, the company expects its inventory levels to jump to 155 days from previously expected levels of 135-140 days. The company also cut its gross margin guidance by 1%. Analysts followed the company's guidance and lowered estimates for 2004 and 2005. The company's biggest competitor, Altera (NASDAQ:ALTR) also cut its sales projections for the third quarter. With widespread inventory and demand issues in the industry, it may be best to wait for estimates to turn around before opening or deepening a position in the stock. Below is a synopsis of why these two stocks have a Zacks Rank of 4 (Sell) and should also most likely be sold or avoided for the next 1 to 3 months. Note that a #4/Sell rating is applied to 15% of all the stocks we rank: Fifth Third Bancorp (NASDAQ:FITB) is a registered financial holding company and a multi-bank holding company. They engage primarily in commercial, retail and trust banking, data processing data processing or information processing, operations (e.g., handling, merging, sorting, and computing) performed upon data in accordance with strictly defined procedures, such as recording and summarizing the financial transactions of a services, investment advisory services advisory services advisory services provided to the public, in their capacity as owners and managers of animals, are an important part of veterinary science. They may be provided by government bureaux, by commercial companies who deal in pharmaceuticals or animals or animal and leasing activities. The company recently reported second quarter earnings that were in line with guidance. However, analysts do have some concerns about the quality of the company's loans and long- term borrowings, which may put downward pressure on margins. The company's mid-quarter update did drive analysts to slightly lower their estimates in light of positive trends in charge-offs and a steepening yield curve compressing net interest margins. Fifth Third does have strong momentum in a number of areas, but investors may want to hold off until estimates start rising again. Eyetech Pharmaceutical, Inc. (NASDAQ:EYET) is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye. Its lead product candidate is Macugen, which has the potential to treat several diseases of the eye, such as: wet age-related macular degeneration Age-related macular degeneration (ARMD) Degeneration of the macula (the central part of the retina where the rods and cones are most dense) that leads to loss of central vision in people over 60. (AMD (Advanced Micro Devices, Inc., Sunnyvale, CA, www.amd.com) A major manufacturer of semiconductor devices including x86-compatible CPUs, embedded processors, flash memories, programmable logic devices and networking chips. ), diabetic macular edema macular edema Ophthalmology Waxing and waning retinal thickening due to the accumulation of fluid, seen in Pts with diabetic retinopathy, seen with a binocular slit lamp or stereoscopic fundus photography; while ME has no visual consequences, it is often (DME (Distributed Management Environment) A network monitoring and control protocol defined by the Open Software Foundation (now The Open Group). DME was not widely used. DME - Distributed Management Environment ), and retinal vein occlusion Retinal Vein Occlusion Definition Retinal vein occlusion refers to the closure of the central retinal vein that drains the retina or to that of one of its branches. . Analysts expect that the drug could take off, but it will face significant competition from other drugs on the market. In the meantime Adv. 1. in the meantime - during the intervening time; "meanwhile I will not think about the problem"; "meantime he was attentive to his other interests"; "in the meantime the police were notified" meantime, meanwhile , the company's expenses to prepare for the drug's launch are incurring serious costs and loss estimates for 2004 have widened -49 cents, or -38% to -$1.77. Revenue estimates once Macugen launches are as high as $1 billion, but investors may want to see whether those predictions play out before increasing exposure to the company. To truly take advantage of the Zacks Rank, you need to first understand how it works. That's why we created the free special report; "Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions." Download your free copy now to prosper in the years to come. http://at.zacks.com/?id=93 About the Zacks Rank For over 15 years the Zacks Rank has proven that "Earnings estimate revisions are the most powerful force impacting stock prices." Since inception in 1988 the #1 Ranked stocks have generated an average annual return of +33.1% compared to the (a)S&P 500 return of only +11.97%. Also note that the Zacks Rank system has just as many Strong Sell recommendations (Rank #5) as Strong Buy recommendations (Rank #1). And since 1988 the S&P 500 has outperformed the Zacks #5 Ranked Strong Sells by 141.8% annually (11.97% vs. 4.5% respectively). Thus, the Zacks Rank system can truly be used to effectively manage the trading in your portfolio. For continuous coverage of Zacks #1 and #5 Ranked stocks, then get your free subscription to "Profit from the Pros" e-mail newsletter where we highlight stocks to buy and sell using our time tested stock evaluation model. http://at.zacks.com/?id=94 The Zacks Rank, and all of its recommendations, is created by Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. , Inc. Zacks.com displays the Zacks Rank with permission from Zacks Investment Research, Inc. on its web site for individual investors. About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://at.zacks.com/?id=95 Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Disclaimer: The Zacks Rank performance is the total return of equal weighted simulated portfolios consisting of those stocks with the indicated Zacks Rank net of fees. Results reflect the reinvestment Reinvestment Using dividends, interest and capital gains earned in an investment or mutual fund to purchase additional shares or units, rather than receiving the distributions in cash. 1. In terms of stocks, it is the reinvestment of dividends to purchase additional shares. of dividends and other earnings. Simulated results do not represent actual trading and may not reflect the impact that economic and market factors might have had on decision-making if an adviser were actually managing a client's money. (a) The S&P 500 Index is a well-known, unmanaged index of the prices of 500 large-company common stocks, mainly blue-chip stocks, selected by Standard & Poor's. The S&P 500 Index assumes reinvestment of dividends but does not reflect advisory fees. An investor cannot invest directly in an index. Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion